![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Brazilian Regulator Approves Sinovac’s Phase 3 COVID-19 Vaccine Trial
Brazilian Regulator Approves Sinovac’s Phase 3 COVID-19 Vaccine Trial
July 8, 2020
Beijing-based Sinovac has received approval from Brazil’s Health Regulatory Agency to begin phase 3 trials of CoronaVac, its COVID-19 vaccine candidate, and said it plans to begin enrollment this month.
The experimental vaccine uses an inactivated form of the coronavirus to generate an immune response. The phase 3 study will include 9,000 healthcare professionals across 12 clinical sites.
CoronaVac showed promise in a phase 2 clinical trial, in which it induced neutralizing antibodies in 90 percent of participants.
Upcoming Events
-
21Oct